Key Points
- BioNTech CEO Ugur Sahin sold 17,000 shares at an average price of $97.46, generating approximately $1.66 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings by 7.94% to 197,209 shares.
- The sale followed multiple recent insider sales, including 32,000 shares on September 30 and additional sales throughout September, indicating a sustained pattern of planned share disposals.
- BioNTech shares opened at $96.90, while analysts maintained a generally positive outlook with a consensus “Moderate Buy” rating and a $126 average price target. However, the company recently reported a quarterly revenue decline of 59.5% year over year and missed earnings expectations.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 17,000 shares of the business's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $97.46, for a total value of $1,656,820.00. Following the sale, the chief executive officer owned 197,209 shares in the company, valued at approximately $19,219,989.14. The trade was a 7.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total value of $3,139,840.00.
- On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total value of $3,347,980.00.
- On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total value of $2,664,630.00.
- On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
- On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total transaction of $2,982,000.00.
- On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
- On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
- On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
- On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
- On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
BioNTech Trading Up 0.1%
Shares of BNTX opened at $96.90 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The firm has a 50 day simple moving average of $98.81 and a 200-day simple moving average of $95.01. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The stock has a market cap of $24.50 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same quarter in the prior year, the firm earned ($1.60) earnings per share. The company's revenue for the quarter was down 59.5% on a year-over-year basis. Equities analysts forecast that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.
Institutional Investors Weigh In On BioNTech
A number of hedge funds and other institutional investors have recently made changes to their positions in BNTX. Flossbach Von Storch SE acquired a new position in BioNTech in the second quarter valued at $207,142,000. First Trust Advisors LP boosted its stake in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after buying an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in BioNTech in the 2nd quarter worth about $39,385,000. SEB Asset Management AB purchased a new stake in BioNTech in the 1st quarter valued at about $17,804,000. Finally, Bank of America Corp DE grew its holdings in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after buying an additional 166,432 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on BNTX shares. Morgan Stanley decreased their price objective on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 8th. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a report on Monday, July 6th. UBS Group reaffirmed a "buy" rating on shares of BioNTech in a research note on Wednesday, September 16th. Citigroup lowered their price target on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a report on Wednesday, August 5th. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $126.00.
View Our Latest Research Report on BNTX
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.
BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
